PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 33336605-9 2021 When cells were pretreated with azithromycin and exposed to 5% CSE for 3 h, there was a significant dose-dependent decrease in the expression of IL-6 mRNA. Azithromycin 32-44 interleukin 6 Homo sapiens 145-149 33336605-11 2021 Conclusion: Pretreatment with azithromycin decreased the expression of IL-6 and IL-8 mRNA and the release of IL-8 in bronchial epithelial cells exposed to cigarette smoke. Azithromycin 30-42 interleukin 6 Homo sapiens 71-75 33628506-14 2021 The administration of azithromycin to the Control group increased CRP and IL-6 levels, while reduced IL-10 and TNF-alpha on day 7 (p < 0.0001) compared with day 1. Azithromycin 22-34 interleukin 6 Homo sapiens 74-78 33336605-10 2021 A final concentration of 9 microg/mL of azithromycin was sufficient to decrease IL-6, IL-8 mRNA, and extracellular IL-8 levels. Azithromycin 40-52 interleukin 6 Homo sapiens 80-84 33414242-2 2021 In a predefined substudy of the original AMAZES protocol (500 mg, three times a week for 48 weeks), we report that AZM treatment reduces key sputum inflammatory proteins (interleukin (IL)-6, IL-1beta and extracellular DNA), which is more evident in non-eosinophilic asthma (NEA). Azithromycin 115-118 interleukin 6 Homo sapiens 171-189 33396644-7 2020 In response to LPS stimulation, the gene expression levels of IL-6 and IL-8 in hGFs increased due to AZM in a concentration-dependent manner, and phosphorylation of nuclear factor kappa B (NF-kappaB) was also promoted. Azithromycin 101-104 interleukin 6 Homo sapiens 62-66 33396644-10 2020 Thus, AZM may increase the expression of IL-6 and IL-8 under LPS stimulation to modify the inflammatory response and increase the expression of MMP-1 to promote connective tissue remodeling. Azithromycin 6-9 interleukin 6 Homo sapiens 41-45 32905367-2 2020 The present study aimed to explore the clinical efficacy of azithromycin combined with doxycycline in patients with NGU and its effect on serum levels of inflammatory cytokine interleukin-6 (IL-6). Azithromycin 60-72 interleukin 6 Homo sapiens 176-189 32920000-6 2020 Chloroquine/hydroxychloroquine + azithromycin interacted with 6 genes (CCL2, CTSB, CXCL8, IL1B, IL6 and TNF), whereas chloroquine and azithromycin affected two additional genes (BCL2L1 and CYP3A4), which might be a reason behind a greater number of consequential diseases. Azithromycin 33-45 interleukin 6 Homo sapiens 96-99 32920000-7 2020 In contrast to lopinavir/ritonavir, chloroquine/hydroxychloroquine + azithromycin downregulated the expression of TNF and IL6. Azithromycin 69-81 interleukin 6 Homo sapiens 122-125 32905367-2 2020 The present study aimed to explore the clinical efficacy of azithromycin combined with doxycycline in patients with NGU and its effect on serum levels of inflammatory cytokine interleukin-6 (IL-6). Azithromycin 60-72 interleukin 6 Homo sapiens 191-195 25058850-6 2015 MDP (an NLRC2 agonist), NAC and AZM, but not Tri-DAP (an NLRC1 agonist), increased IL-6 production in CF cells, indicating that in CF cells IL-6 upregulation is independent of NLRC1, but involves the activation of NLRC2. Azithromycin 32-35 interleukin 6 Homo sapiens 83-87 30348950-9 2018 Azithromycin showed the same effect in imitated SLE macrophages, with distinct Akt phosphorylation at 30 min and 12 h. After inhibiting Akt phosphorylation by LY294002, the down-regulation of CD80, IL-1beta, IL-6, and TNF-alpha caused by azithromycin raised again, meanwhile, the up-regulation of CD206, Arg-1, Fizz-1, and IL-10 due to azithromycin was abolished. Azithromycin 0-12 interleukin 6 Homo sapiens 208-212 27664570-3 2016 We found that AZM down-regulated CD80, CD86, and HLA-DR expression in lipopolysaccharide (LPS)-stimulated DCs and suppressed interleukin (IL)-6, IL-10, IL-12, and tumor necrosis factor-alpha production in these cells. Azithromycin 14-17 interleukin 6 Homo sapiens 125-143 32534189-4 2020 In vitro studies have demonstrated the capacity of azithromycin in reducing production of pro-inflammatory cytokines such as IL-8, IL-6, TNF alpha, reduce oxidative stress, and modulate T-helper functions. Azithromycin 51-63 interleukin 6 Homo sapiens 131-135 29715306-10 2018 AZI inhibited R848-induced TNF, IL-1beta, IL-6 and IL-10, and LPS-induced IL-1beta and IL-10. Azithromycin 0-3 interleukin 6 Homo sapiens 42-46 28664473-8 2017 The expression levels of VEGF, IL-6, and IL-10 also decreased in response to treatment with QTF or AZM. Azithromycin 99-102 interleukin 6 Homo sapiens 31-35 28535933-11 2017 Additional ex vivo studies confirmed reduced induction of IL-6 (P = 0.017) and CXCL8/IL-8 (P = 0.005) with azithromycin. Azithromycin 107-119 interleukin 6 Homo sapiens 58-62 25058850-6 2015 MDP (an NLRC2 agonist), NAC and AZM, but not Tri-DAP (an NLRC1 agonist), increased IL-6 production in CF cells, indicating that in CF cells IL-6 upregulation is independent of NLRC1, but involves the activation of NLRC2. Azithromycin 32-35 interleukin 6 Homo sapiens 140-144 21726210-6 2012 KEY RESULTS: Azithromycin (1.5-50 microM) dose-dependently inhibited gene expression and/or release of M1 macrophage markers (CCR7, CXCL 11 and IL-12p70), but enhanced CCL2, without altering TNF-alpha or IL-6. Azithromycin 13-25 interleukin 6 Homo sapiens 204-208 24806810-5 2015 RESULTS: P. gingivalis LPS induced cytokine/chemokine (IL-6, IL-8, MCP-1, and GRO) protein production in HGFs, and this effect was suppressed by azithromycin at all concentrations tested. Azithromycin 145-157 interleukin 6 Homo sapiens 55-59 23199585-7 2013 CAM and AZM induced a dose-dependent suppression of spontaneous TNF-alpha, sTNFR2, IL-6, IL-8 and CCL18 production (p<0.05). Azithromycin 8-11 interleukin 6 Homo sapiens 83-87 33894712-10 2021 A negative correlation was observed between AZM concentration in lung tissue and interleukin-6 (IL-6) expression. Azithromycin 44-47 interleukin 6 Homo sapiens 81-94 21848430-8 2012 We observed inhibition of cytokines (interleukin [IL]-1beta (beta), IL-6, IL-8, IL-10, and tumor necrosis factor-alpha) in the presence of azithromycin in EB-stimulated cells from both fertile and infertile women with primary and recurrent C. trachomatis infection. Azithromycin 139-151 interleukin 6 Homo sapiens 68-72 22131344-7 2012 Azithromycin, added 2 h before activation of iDCs with LPS, enhanced IL-10 release and inhibited IL-6, IL-12p40, CXCL10, CXCL11, and CCL22 release. Azithromycin 0-12 interleukin 6 Homo sapiens 97-101 22993937-3 2012 The treatment with azithromycin, in addition to the high eradication rates, was also evident of its effect on the cytokine levels in the patients, that was characteristic of a significant increase of the IFN-gamma level and a decrease of the IL-1beta and IL-6 levels in the blood. Azithromycin 19-31 interleukin 6 Homo sapiens 255-259 21315154-4 2011 Three of the four tested macrolides, azithromycin, clarithromycin and roxithromycin, exhibited pronounced, concentration-related reduction of IL-1beta, IL-6, IL-10, TNF-alpha, CCL3, CCL5, CCL20, CCL22, CXCL1, CXCL5, and G-CSF release. Azithromycin 37-49 interleukin 6 Homo sapiens 152-156 17667842-8 2007 AZM significantly reduced the IL-6 and IL-8 production to the levels similar to control. Azithromycin 0-3 interleukin 6 Homo sapiens 30-34 12384353-3 2002 Azithromycin decreased the tumor necrosis factor alpha (TNF-alpha), interleukin-1beta (IL-1beta), and IL-6 production from Stx-treated human peripheral mononuclear cells or monocytes to a greater extent than did clarithromycin. Azithromycin 0-12 interleukin 6 Homo sapiens 102-106 12208321-7 2002 A continuous fall in chemokine and interleukin-6 serum concentrations, within the non-pathological range, accompanied a delayed down-regulation of the oxidative burst and an increase in apoptosis of neutrophils up to 28 days after the last azithromycin dose. Azithromycin 240-252 interleukin 6 Homo sapiens 35-48 10839761-4 2000 Azithromycin reduced a global rank sum score of 4 inflammatory markers (C-reactive protein [CRP], interleukin [IL]-1, IL-6, tumor necrosis factor-alpha; P=.011) and a global rank sum change score (+/-SD) (from 535+/-201 to 587+/-190; P=.027) at 6 (but not 3) months. Azithromycin 0-12 interleukin 6 Homo sapiens 118-122 10853849-6 2000 There were significant (p<0.05) pre- to post-exposure increases in total cells, neutrophils, IL-6 and IL-8 in both the azithromycin and placebo arms. Azithromycin 122-134 interleukin 6 Homo sapiens 96-100 34540066-0 2021 Total serum IL-6 and TNF-C levels in children with bronchopneumonia following treatment with methylprednisolone in combination with azithromycin. Azithromycin 132-144 interleukin 6 Homo sapiens 12-16 34540066-1 2021 OBJECTIVE: To analyze the expression levels of total serum interleukin (IL)-6 and tumor necrosis factor (TNF)-C in children with bronchopneumonia treated by methylprednisolone in combination with azithromycin. Azithromycin 196-208 interleukin 6 Homo sapiens 59-77 15252403-8 2004 Incubation with 0.016 microg/mL azithromycin decreased IL-6 levels to a mean of 1516 +/- 402 pg/mL, and incubation with 0.125 and 1 microg/mL azithromycin decreased IL-6 to 871 +/- 364 and 752 +/- 403 pg/mL, respectively. Azithromycin 32-44 interleukin 6 Homo sapiens 55-59 15252403-8 2004 Incubation with 0.016 microg/mL azithromycin decreased IL-6 levels to a mean of 1516 +/- 402 pg/mL, and incubation with 0.125 and 1 microg/mL azithromycin decreased IL-6 to 871 +/- 364 and 752 +/- 403 pg/mL, respectively. Azithromycin 32-44 interleukin 6 Homo sapiens 165-169 15252403-10 2004 The interaction of C pneumoniae with azithromycin treatment was significant, indicating an inhibitory effect of azithromycin on C pneumoniae-induced IL-6 production. Azithromycin 37-49 interleukin 6 Homo sapiens 149-153 15252403-10 2004 The interaction of C pneumoniae with azithromycin treatment was significant, indicating an inhibitory effect of azithromycin on C pneumoniae-induced IL-6 production. Azithromycin 112-124 interleukin 6 Homo sapiens 149-153 15252403-16 2004 Azithromycin reduces C pneumoniae-induced IL-6 production, but not fibrinogen production, by human hepatocytes. Azithromycin 0-12 interleukin 6 Homo sapiens 42-46 12623273-5 2003 When azithromycin was added to infected cultures of FSC at 0 or 48 h after infection, the level of IL-6 production was very low. Azithromycin 5-17 interleukin 6 Homo sapiens 99-103 34088250-0 2022 NSAIDs/Nitazoxanide/Azithromycin Repurposed for COVID-19: Potential Mitigation of the Cytokine Storm Interleukin-6 Amplifier via Immunomodulatory Effects. Azithromycin 20-32 interleukin 6 Homo sapiens 101-114 33937285-5 2021 Among such class of drugs, azithromycin is described as azalide and is well-known for its ability to decrease the production of pro-inflammatory cytokines, including matrix metalloproteinases, tumor necrosis factor-alpha, interleukin (IL)-6, and IL-8. Azithromycin 27-39 interleukin 6 Homo sapiens 222-240 33894712-10 2021 A negative correlation was observed between AZM concentration in lung tissue and interleukin-6 (IL-6) expression. Azithromycin 44-47 interleukin 6 Homo sapiens 96-100